literature

HIV mutation literature information.

Understanding the co-evolutionary molecular mechanisms of resistance in the HIV-1 Gag and protease.

PMID: 34253143 2021 Journal of biomolecular structure & dynamics

Abstract: Here we showed that distinct changes in PR's active site, flap and elbow regions due to several PR resistance mutations (L10F, M46I, I54V, L76V, V82A) were found to alter LPV and DRV drug binding.

High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil.

PMID: 34212033 2021 BioMed research international

Result: Only half of the individuals had used PI (n = 46/82), only 17% of individuals presented DRMs associated with protease inhibitors (n = 14), and the most frequent mutations were V82A/L/M (6/82; 7.3%) and I54L/M/V (5/82; 6%), L90M (4/82; 4.8%), and M46L/I (4/82; 4.8%) (Figure 1).

Highly drug-resistant HIV-1 protease reveals decreased intra-subunit interactions due to clusters of mutations.

PMID: 31920003 2020 The FEBS journal

Result: M46I and I54V mutations co-occur frequently in drug resistance.

Result: PRS17 contains a cluster of three flap mutations, M46L, G48V, and I54V, which primarily affect the conformation of the flaps.

Result: Adding M46I and I54V mutations to a RTV-resistant mutant was shown to improve catalytic efficiency while sustaining resistance.

Genotyping and antiretroviral drug resistance of human immunodeficiency Virus-1 in Jazan, Saudi Arabia.

PMID: 33285702 2020 Medicine

Discussion: These results are inconsistent with the previous study of Jamjoom et al, who reported that the most prevalent PI mutations were I54 V, L90 M, V82A, M46I, I50 V, and D30N.

HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.

PMID: 32041622 2020 AIDS research and therapy

Table: I54V

HIV-1 subtypes and drug resistance mutations among female sex workers varied in different cities and regions of the Democratic Republic of Congo.

PMID: 32045455 2020 PloS one

Result: The two non-polymorphic accessory mutations associated with PI mutations were L33F and I54V, and were observed in three PI resistant patients.

Table: I54V

High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.

PMID: 32049783 2020 Medicine

Abstract: Additionally, and at a lower level, protease inhibitor (PI)-resistance mutations, M46I, I54 V, V82A, L90 M, and I471 V, were also present in the sequences from antiretroviral therapy (ART)-experienced individuals.

High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.

PMID: 32105319 2020 The Journal of antimicrobial chemotherapy

Table: I54V

HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.

PMID: 32556165 2020 The Journal of antimicrobial chemotherapy

Result: As shown in Figure 4(a), recombinant viruses from PT1, PT3 and PT6 were fully susceptible to darunavir in accordance with the high genetic barrier of the drug, even in the presence of I54V and V82A protease mutations, as predicted by Stanford for the T2 clonal viruses 5 and 8 from PT3.

Result: Similarly, viruses from PT1, PT3 and PT6 were fully susceptible to lopinavir with the exception of the clonal viruses 5 and 8 from PT3 at T2 (Table 4), which carry I54V and V82A protease mutations able to replicate at 100 nM lopinavir (Figure 4b).

Discussion: In addition, we detected a small cluster of sequences from PT3 at T2 with mutations I54V and V82A in the protease

Patterns of acquired HIV-1 drug resistance mutations and predictors of virological failure in Moshi, Northern Tanzania.

PMID: 32986709 2020 PloS one

Result: One participant (K38) who had previously used ritonavir-boosted lopinavir had L24I, L33F, I54V, and V82A mutations which together reduce the susceptibility of ritonavir-boosted lopinavir.

Table: I54V

Browser Board

Co-occurred Entities

Filtrator